Editorial team
ioQuanta Research Desk
-
Evidence date ·How did body mass index relate to survival across kidney cancer treatments?
Review or Meta-AnalysisTracked over timeA 2024 review linked higher body mass index to longer survival with immunotherapy plus targeted drugs; immunotherapy-only studies showed no clear survival link.
-
Evidence date ·What can body mass index tell us about immunotherapy outcomes?
Review or Meta-AnalysisTracked over timeA review of 20 studies linked higher body mass index to longer survival and more immune-related side effects during immunotherapy; results varied by cancer and sex.
-
Evidence date ·What lignin, xylan and cellulose bring to drug carriers
Review or Meta-AnalysisA 2021 review describes far greater drug release from one xylan carrier with rat cecal and colonic contents, and compares lignin and cellulose carriers.
-
Evidence date ·Winery leftovers can become plastic ingredients in two very different ways
Review or Meta-AnalysisA 2021 review describes two uses for winery waste: sugars for polymer ingredients and particles that can stiffen bioplastics while reducing strength under tension.
-
Evidence date ·Why can linking immune cells to cancer cells work differently by setting?
Review or Meta-AnalysisA 2021 review contrasts catumaxomab’s use for cancer-related abdominal fluid with a separate intravenous study that reported serious liver toxicity.
-
Evidence date ·Could lining up tiny fillers change what a material can do?
Review or Meta-AnalysisA 2021 review argues that arranging tiny fillers could give polymer composites new functions, while ways to produce those patterns remain underexplored.
-
Evidence date ·Why have T-cell engagers advanced further in blood cancers than solid tumors?
Review or Meta-AnalysisTracked over timeBy linking T cells to cancer cells, engagers have shown benefit in leukemia and myeloma. A 2026 review explains why solid tumors are harder to reach and target safely.
-
Evidence date ·How does one lipid particle link a T cell to a tumor cell?
Peer-Reviewed PaperTracked over timeA lipid particle with CD3- and HER2-binding fragments helped T cells kill HER2-positive tumor cells in models; a third binder targets PD-L1.
-
Evidence date ·One T-cell bridge can carry three ways to recognize myeloma
Peer-Reviewed PaperTracked over timeCompared with single-target versions, three-target particles increased myeloma-cell killing in marrow-like cultures and delayed tumor progression in mice.
-
Evidence date ·How do immune cells reach a tumor inside a chip?
Review or Meta-AnalysisA 2021 review explains why a vessel-like barrier matters for tumor chips and how image analysis can track immune-cell behavior as conditions change.